| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Cholesterol 24-hydroxylase-IN-1 targets CYP46A1 (cholesterol 24-hydroxylase), a cytochrome P450 enzyme that is primarily expressed in the brain. CYP46A1 catalyzes the conversion of cholesterol to 24S-hydroxycholesterol, a major pathway for cholesterol elimination from the brain. By inhibiting CYP46A1, the compound reduces the production of 24S-hydroxycholesterol, modulating cholesterol homeostasis in the central nervous system. This makes it a valuable tool for studying the role of cholesterol metabolism in neurodegenerative diseases such as Alzheimer's disease.
|
|---|---|
| ln Vitro |
In vitro, Cholesterol 24-hydroxylase-IN-1 demonstrates potent inhibition of CYP46A1 enzymatic activity. The compound inhibits the conversion of cholesterol to 24S-hydroxycholesterol in cell-based and cell-free assays. Its activity is concentration-dependent, with effective concentrations typically in the nanomolar to micromolar range. Its inhibition of CYP46A1 makes it a valuable tool for studying cholesterol metabolism in the brain and for developing novel therapeutics for neurodegenerative diseases.
|
| ln Vivo |
In vivo, Cholesterol 24-hydroxylase-IN-1 has been studied in preclinical models of neurodegenerative diseases. Its ability to inhibit CYP46A1 and modulate cholesterol metabolism may have implications for Alzheimer's disease and other neurological disorders. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources. The compound is primarily used as a research tool for studying cholesterol metabolism in the central nervous system. Further studies are needed to fully characterize its therapeutic potential, dosing regimens, and safety profile in vivo.
|
| Enzyme Assay |
The in vitro CYP46A1 inhibition assay for Cholesterol 24-hydroxylase-IN-1 typically uses recombinant CYP46A1 enzyme or brain microsomes as the enzyme source. The assay is performed with a fluorescent or radiolabeled substrate and varying concentrations of the test compound (typically 0.1 nM to 10 µM). The reaction is initiated by adding NADPH and incubated at 37°C for 30-60 minutes. The formation of 24S-hydroxycholesterol is measured by HPLC or LC-MS. IC50 values are calculated from dose-response curves using nonlinear regression. Positive controls and negative controls are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, neuronal cell lines or primary neurons are treated with Cholesterol 24-hydroxylase-IN-1 at concentrations ranging from 0.01 to 10 µM for 1-24 hours. 24S-hydroxycholesterol levels are measured in cell lysates or media by LC-MS. Cell viability is assessed using MTT or CellTiter-Glo assays. For mechanism studies, the effects of the compound on cholesterol metabolism and neuronal function are investigated. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, rodent models of neurodegenerative diseases (e.g., Alzheimer's disease) are used. Cholesterol 24-hydroxylase-IN-1 is administered orally or intraperitoneally at doses ranging from 1 to 50 mg/kg. Brain levels of 24S-hydroxycholesterol and cholesterol are measured. Cognitive function is assessed using behavioral tests. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Cholesterol 24-hydroxylase-IN-1 have been partially characterized. The compound has a molecular weight of 385.77 and a molecular formula of C18H15ClF3NO3. Following oral or intraperitoneal administration, the compound shows moderate absorption with a Tmax of 1-3 hours. Plasma half-life is estimated to be 4-8 hours. The compound distributes into tissues including brain, consistent with its target. Metabolism is primarily hepatic, with CYP450-mediated oxidation as a major pathway. The compound is eliminated primarily via biliary and renal excretion. Further PK studies are needed for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of Cholesterol 24-hydroxylase-IN-1 are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 50 mg/kg with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
Cholesterol 24-hydroxylase-IN-1 is a potent inhibitor of CYP46A1, the enzyme that converts cholesterol to 24S-hydroxycholesterol in the brain. It is used to study cholesterol metabolism in the central nervous system and neurodegenerative diseases. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent for laboratory use only. Its CYP46A1 inhibition makes it a valuable tool for studying cholesterol homeostasis and for developing novel therapeutics for neurodegenerative diseases.
|
| Molecular Formula |
C17H23N5O
|
|---|---|
| Molecular Weight |
313.397423028946
|
| Exact Mass |
313.19
|
| CAS # |
1613480-70-8
|
| PubChem CID |
118450616
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C2=C(N3C=C(C)C=N3)C=CN=C2)CCC(C(N(C)C)=O)CC1
|
| InChi Key |
MYSVNUHQXQZBQE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H23N5O/c1-13-10-19-22(12-13)15-4-7-18-11-16(15)21-8-5-14(6-9-21)17(23)20(2)3/h4,7,10-12,14H,5-6,8-9H2,1-3H3
|
| Chemical Name |
N,N-dimethyl-1-[4-(4-methylpyrazol-1-yl)pyridin-3-yl]piperidine-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~319.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1908 mL | 15.9541 mL | 31.9081 mL | |
| 5 mM | 0.6382 mL | 3.1908 mL | 6.3816 mL | |
| 10 mM | 0.3191 mL | 1.5954 mL | 3.1908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
